Introduction
============

Venous thrombosis (VT), including deep vein thrombosis (DVT) and pulmonary embolism (PE), affects about 1 200 000 individuals each year in Europe and is thus the third most common cardiovascular disease after coronary artery disease and stroke.[@suaa008-B1] It is a severe disorder that leaves many patients (25--50%) with a debilitating post-thrombotic syndrome[@suaa008-B2] and whose PE manifestation kills many of them (6% acute and 20% after 1 year).[@suaa008-B3] About 50% of VT are unprovoked, i.e. they occur without clear external factors like surgery, trauma, immobilization, hormone use or cancer. The annual recurrent rate is ∼6% and about 25% of patients with unprovoked VT will face a recurrent event after a 6-month course of anticoagulant treatment.[@suaa008-B4] Thus, the secondary prevention of VT in this specific population group of patients with a first unprovoked VT is a major health issue.

There is an urgent need to better understand the pathophysiological mechanisms leading to VT in order to develop targeted therapeutic and preventative strategies to save lives, improve quality of life and reduce healthcare costs. Effective preventative options are available in the form of anticoagulant treatments, but these are associated with major bleeding complications. There are unmet needs to develop predictive biomarkers with high sensitivity and specificity for accurate identification of patients who will develop a recurrence, to avoid unacceptably high risk of bleeding complications in patients at low risk of recurrence. Indeed, preventing thrombosis without inducing bleeding is the holy grail of anticoagulant therapy. Currently, there are no commercially available anticoagulants that achieve this.

Predicting the risk of recurrence and discriminating between fatal (PE) and non-fatal (DVT) events in unprovoked VT patients remain challenging. There is so far no established biomarkers that serve these aims, even if D-dimers measurement has been proposed[@suaa008-B5] but lacks specificity. We here propose a comprehensive microRNA (miRNA) profiling from plasma samples of VT patients aimed at discovering miRNA-derived biomarkers discriminating between PE and DVT and associated with VT recurrence. MicroRNAs represent a class of small (∼22 nucleotides) non-coding RNAs that participate in genes post-transcriptional regulation.[@suaa008-B6] It is now well-established that miRNAs are involved in the development of human diseases, in particular, cardiovascular ones.[@suaa008-B7] Several genes participating to thrombosis associated mechanisms have already been suspected to be subject to miRNA regulation.[@suaa008-B8] So far, epidemiological studies looking for association of plasma miRNAs with VT outcomes are still sparse. Using plasma samples of 20 VT cases and 20 healthy individuals, Starikova *et al*.[@suaa008-B12] assessed the association of 97 miRNAs with VT risk among which 9 were found significantly (*P* \< 0.05) associated with the outcome. As for Wang *et al*.,[@suaa008-B13] by looking for the association of 110 miRNAs with the risk of VT recurrence in plasma samples of 39 cases and 39 controls, 12 miRNAs were identified. None of these observations, which were obtained on miRNA data profiled using RT-qPCR techniques, have yet been replicated.

Briefly, we here performed plasma miRNA profiling in 391 VT patients using a next-generation sequencing technology and assessed the association of identified miRNAs with several haemostatic traits and VT associated clinical outcomes. Association analyses were conducted using an original Bayesian network (BN) inference strategy aimed at identifying miRNAs with the highest abilities to serve as relevant biomarkers. In addition, we integrated genome-wide genotype data with miRNA expression levels in order to identify miRNAs that are under strong genetic control.

Methods
=======

The MARTHA microRNA sequencing study
------------------------------------

The MARseille THrombosis Association project refers to a collection of VT patients recruited at the La Timone Hospital in Marseille, France, initially between 1994 and 2005 and further extended over the 2010--12 period. Detailed description of this collection has already been previously provided.[@suaa008-B14]

The present study relies on a subsample of 391 VT patients that had been previously genotyped for genome-wide polymorphisms using dedicated genotyping array[@suaa008-B15]^,^[@suaa008-B16] and with available plasma samples. For each sample, total RNA was extracted from 400 µL citrate plasma sample using miRNeasy Serum/Plasma kit from Qiagen. From 6 µL of total RNA, plasma miRNA libraries were then prepared with NEBNext Multiplex Small RNA Library Prep Set for Illumina. The manufacturer's protocol was followed, with an optimized size selection method via Ampure XP beads, a specific dilution of adapters to 1/10, and 15 cycles of PCR amplification, using adapter sequences GATCGGAAGAGCACACGTCTGAACTCCAGTCAC and CGACAGGTTCAGAGTTCTACAGTCCGACGATC for 3' and 5' ends, respectively. Detailed characteristics of the experimental protocol for libraries preparation and sequencing have already been described.[@suaa008-B17]

MicroRNA alignment and quantification processes
-----------------------------------------------

Sequenced data were processed with the bioinformatic OptimiR pipeline[@suaa008-B17] in order to detect and quantify miRNAs. Briefly, OptimiR aligned miRNAs to a library composed of mature miRNA references sequences from miRBase 21.[@suaa008-B18] For miRNA integrating genetic variants in their sequence (called polymiRs), the reference library was upgraded by OptimiR with sequences integrating alternative alleles. Ambiguous alignments were resolved using a scoring algorithm that keeps only the most likely alignment while considering the frequent post-transcriptional modifications that miRNAs can undergo.[@suaa008-B19] Reads aligned on polymiRs were kept if they were consistent with the sample's genotype, otherwise, they were discarded.[@suaa008-B17]

From the resulting miRNA abundances, we performed several quality assessments in order to discard unreliable data. First, samples that were poorly sequenced, i.e. with \<100 000 reads aligned, were discarded (*n* = 3) as well as samples identified to be haemolyzed (*n* = 34). The degree of haemolysis was determined based on the optical density at 414 nm, and values exceeding 0.2 were defined as haemolyzed samples.[@suaa008-B20] Finally, in order to retain only highly expressed miRNAs, we kept only those with at least five counts in at least 75% of the remaining samples.

Abundances were then normalized using the rlog method from the DESeq2 R library.[@suaa008-B21] This normalization process takes into account differences in library sizes due to library preparation and sequencing protocols, and stabilize variance across miRNAs and samples to respect homoscedasticity constraints for further analysis. Principal component analysis (PCA) was applied to normalized abundances in order to identify individuals with outliers miRNA profiles. Individuals deviating by 3 SD from the centres of the first four PCAs (*n* = 10) were further excluded from downstream analyses, leaving 344 individuals for BN and association analyses.

Bayesian network analysis
-------------------------

A BN is a probabilistic directed acyclic graphical model that represents relationships among a large number of variables (here mainly miRNAs) with the aim of modelling the dependencies/interactions and conditional independencies between variables.[@suaa008-B22]^,^[@suaa008-B23] Generally, any BN is defined by a directed acyclic graph structure *G* = (*V*,*E*) where *V* is the set of variables and *E* the set of edges representing the directional relationships between variables and *P* a joint probability distribution of the variables in the network. Three types of nodes can be identified in a given BN: the root nodes that are variables found to influence several other variables but are not themselves influenced by any other variables, the internal nodes that are both influenced by and modulate other variables, and finally terminal nodes that are variables that are not identified as influencing others (see *Figure [1](#suaa008-F1){ref-type="fig"}*). Any variable influencing another variable in the network is referred to as a parental node for this later variable. In the following, we will mainly focus on terminal nodes assuming that such nodes, as integrating the cumulative upstream effects of other variables, would serve as more relevant and powerful endophenotypes to be tested in relation to some outcomes of interest. In that context, BN analysis can also be viewed as a data reduction technique since, instead of testing the association of all initial variables with a given outcome, only the terminal nodes will be tested for association, reducing then the multiple testing burden. In this article, BNs will be constructed with the «bnlearn» package[@suaa008-B24] that implements the relatively fast *tabu search* algorithm handling both discrete and continuous variables. In the current application, BNs will be created from all expressed miRNAs but also with the age and sex variables. These two latter variables have been shown to have strong influence on circulating miRNA levels[@suaa008-B25]^,^[@suaa008-B26] and their integration in the BN analysis can then add information to more efficiently model the dependencies and conditional independence between some miRNAs.

![A Bayesian network example. In this illustrative BN example, variables V1, V2, and V3 are root nodes, V4 and V5 are internal nodes, and V6 and V7 are terminal nodes. V3 is also a parental node for V4 which is itself a parental node for V7.](suaa008f1){#suaa008-F1}

Because *tabu search* is a greedy search algorithm, it may end up into a local optimum. To overcome such situation and to assess the stability of the BN analysis in identifying robust terminal nodes, we generated 2000 bootstrapped datasets composed of 95% of the initial samples and for each boostrapped datasets, we randomly shuffled the way the input variables were ordered in the initial dataset. For each shuffled bootstrapped dataset, a BN was constructed and the terminal nodes identified. After 2000 bootstrap, we calculated the number of times a given variable was identified as terminal node.

In order to assess whether the observed distribution of the number of terminal node's occurrences deviates from the null hypothesis of no correlation structure between miRNAs, a permutation strategy was adopted. For each permutation, we randomly selected at least 40 variables whose values were permuted between individuals in order to break down the original data correlation structure. We generated 2000 of such permuted datasets and constructed a BN on each of them. From these permuted BNs, we counted the maximum number of times a given variable (that could be any miRNA, age, or sex) was identified as a terminal node and used this maximum value as a cut-off to identify robust terminal miRNAs in the unpermuted analysis above.

Association analysis with haemostatic traits and clinical outcomes
------------------------------------------------------------------

Identified terminal miRNAs were tested for association with several haemostatic traits available in MARTHA participants (see *Table [1](#suaa008-T1){ref-type="table"}*). Association analyses were performed using linear regression model and adjusted for age, sex, anticoagulant therapy, and combined plasma levels of hsa-let-7d-5p, hsa-let-7g-5p and let-7i-5p measured by qPCR, which serve as a control reference of miRNA levels.[@suaa008-B27] Individuals under anticoagulant therapy at the time of blood sampling were excluded for the analysis on protein C, protein S, and prothrombin time. For association testing, log-transformation was applied to the following variables: Activated Thrombin Generation Potential biomarkers (Endogenous Thrombin Potential, Lagtime), Partial Thromboplastin Time, Factor VIII, Homocystein, Plasminogen Activator Inhibitor-1, Tissue Factor Principal Inhibitor, and von Willebrand Factor.

###### 

Characteristics of the MARTHA miRNA cohort

  Variables                                   *N*   Mean ± SD[^a^](#tblfn1){ref-type="table-fn"}
  ------------------------------------------- ----- ------------------------------------------------
  Gender (male/female)                        344   144/200
  Age (years)                                 344   52.1 ± 14.5
  Smoking (yes/no)                            343   94/249
  BMI (kg/m^2^)                               331   25.86 ± 4.62
  Deep vein thrombosis/pulmonary embolism     344   259/85
  Anticoagulant therapy (yes/no)              344   122/222
  Antithrombin (IU/mL)                        313   102.41 ± 11.59
  Activated partial thromboplastin time (s)   341   33.42 ± 6.02
  D-dimers (µg/mL)                            184   0.39 ± 0.33[^b^](#tblfn2){ref-type="table-fn"}
  FV (IU/mL)                                  150   109.21 ± 22.26
  FVIII (IU/dL)                               294   135.07 ± 48.31
  FXI (IU/mL)                                 336   130.78 ± 31.99
  Fibrinogen (g/L)                            342   3.42 ± 0.66
  Haematocrit (L/L)                           343   0.42 ± 0.03
  Homocysteine (µmol/L)                       304   12.26 ± 5.65
  Platelet count (G/L)                        344   254.62 ± 64.91
  Mean platelet volume (fL)                   344   7.90 ± 0.77
  Haemoglobin (g/dL)                          344   140.42 ± 13.19
  PAI-1 (UI/mL)                               272   12.25 ± 13.44
  Protein C (IU/mL)                           318   99.55 ± 40.56
  Protein S (IU/mL)                           322   81.3 ± 27.49
  TAFI (µg/mL)                                336   15.27 ± 4.72
  TFPI (ng/mL)                                336   14.17 ± 6.84
  vWF (IU/dL)                                 308   154.34 ± 67.74
  Prothrombin time (%)                        344   87.63 ± 27.95
  Thrombin generation                         193   
   Endogeneous thrombin potential (nM⋅min)          1761.44 ± 280.31
   Peak (nM)                                        340.35 ± 57.51
   Lagtime (min)                                    3.34 ± 1.17
  VT recurrence during follow-up (yes/no)     228   41/187

Count data are shown for categorical variables, other reported values were mean ± standard deviation.

In about 50% participants, D-dimers values were below the detection limit (0.22) and thus discarded. Mean and SD were then computed over all D-dimer values \>0.22.

Terminal miRNAs were also tested for association with the DVT vs. PE outcome using a logistic regression model, while a Cox model was used to assess their association with VT recurrence whose information was available in 228 patients only. For the latter analysis, we applied the Cox survival model with left truncature[@suaa008-B28] and adjusted for age, sex, body mass index (BMI), and smoking. To address the multiple testing issue associated with the number of terminal miRNAs that will be tested for association with the phenotypes, we applied a Bonferroni correction based on the effective number of independent variables.[@suaa008-B29]

Genome-wide miR-eQTL analysis
-----------------------------

As MARTHA participants have been typed for high-density genotyping arrays and imputed for common polymorphisms available in the 1000 G reference panel, we performed genome-wide association study (GWAS) on each expressed miRNA for identifying miRNA expression quantitative trait loci (miR-eQTL) using the mach2QTL programme.[@suaa008-B30] Analyses were performed under the assumption of additive genetic effects and adjusting for the following covariates: sex, age of blood collection, anticoagulant prescription, RT-qPCR measured hsa-let-7 combination,[@suaa008-B27] and the four first principal genetic components retrieved from PCA analysis as previously described.[@suaa008-B15]^,^[@suaa008-B16] GWAS results were filtered out for variants with minor allele frequency lower than 0.05 and with imputation criterion *r*^2^ below 0.4. Finally, we combined the results of our miR-eQTL analysis with those previously described by Nikpay *et al*.[@suaa008-B31] and available at <https://zenodo.org/record/2560974> in order to identify additional single nucleotide polymorphism (SNP) × miRNA associations. For this, a random-effect model-based meta-analysis was adopted as implemented in the GWAMA software.[@suaa008-B32] SNP × miRNA associations were considered as *cis* effects when the SNP maps ± 1 Mb from the mature miRNA position. Otherwise, they were considered as *trans*. Any association with *P*-value \<3.2 × 10^−10^ corresponding to the Bonferroni threshold corrected for the number of tested SNP × miRNA associations was considered as genome-wide significant. We also used a miRNA-wide threshold of *P* \< 5 × 10^−8^, the standard statistical threshold generally advocated in the context of a single GWAS, to identify additional suggestive associations.

Results
=======

The MARTHA microRNA cohort
--------------------------

Detailed description of the clinical and biological characteristics of the 344 participants is shown in *Table [1](#suaa008-T1){ref-type="table"}*. Of note, 228 patients have been followed for the risk of recurrence for a mean time period of 11.4 ± 4.3 years. During this period, 41 patients experienced a new VT event.

After the application of the OptimiR workflow, 162 miRNAs were found expressed in the 344 MARTHA participants. Full miRNA data are provided in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S1](#sup1){ref-type="supplementary-material"}*. The most expressed miRNA was the hsa-miR-122-5p ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S1](#sup1){ref-type="supplementary-material"}*), a miRNA known to be mainly expressed in liver and that was previously shown to be amongst the most abundant plasma miRNAs.[@suaa008-B33] Additional highly expressed miRNAs were hsa-miR-486-5p, hsa-miR-92a-3p, and hsa-miR-451a ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S1](#sup1){ref-type="supplementary-material"}*). Of note, the 25 most expressed miRNAs accounted for \>90% of all sequenced reads that were aligned to miRNA mature sequences.

BN analysis of microRNA data
----------------------------

Under the null hypothesis of no specific structure in the miRNA data, all miRNAs were identified as a terminal node at least once and, on average, a miRNA was found as a terminal node in 6.3% ± 3.5 of the permuted BNs, with a maximum of 18.3%. Using the latter threshold, the bootstrap BN analysis identified 15 terminal miRNAs and the number of times each of them was found as a terminal node in boostrapped BNs is shown in *Figure [2](#suaa008-F2){ref-type="fig"}*.

![Percentage of significant terminal miRNAs found in 2000 bootstrapped Bayesian networks. The bootstrap BN analysis identified 15 terminal miRNAs with an occurrence percentage over the significance threshold (18.3%) determined by the permutation analysis.](suaa008f2){#suaa008-F2}

Association of microRNAs' levels with VT-associated biological and clinical traits
----------------------------------------------------------------------------------

The application of the Li and Ji multiple testing procedure[@suaa008-B29] estimated the number of effective independent terminal miRNAs as 14, leading to an adapted Bonferroni threshold of 3.6 × 10^−3^. At this statistical level, only one association between terminal miRNAs and haemostatic traits was detected. Plasma levels of hsa-miR-199b-3p were negatively correlated (*ρ* = −0.17, *P* = 0.0016) with haematocrit levels. Interestingly, this miRNA has recently been reported to associate with VT risk[@suaa008-B12] whose association with haematocrit levels have already been described.[@suaa008-B34]^,^[@suaa008-B35] The full results of the scan for association between miRNAs and haemostatic traits are given in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S2](#sup1){ref-type="supplementary-material"}*.

Of note, the strongest association of terminal miRNAs with recurrence risk was observed for hsa-miR-370-3p \[HR = 1.77 (1.09--2.88), *P* = 0.019\], this miRNA being also the terminal miRNA that discriminated the most between DVT and PE \[OR for PE = 0.72 (0.49--1.05), *P* = 0.090\] (*Table [2](#suaa008-T2){ref-type="table"}*). Of interest, one of our terminal miRNAs, hsa-miR-197-3, was reported to associate with VT recurrence in Wang *et al*.[@suaa008-B13] However, we did not observe here such trend for association \[HR = 0.78 (0.35--1.76), *P* = 0.55\]. Nevertheless, among the nine additional miRNAs reported in Wang *et al*. and also expressed in MARTHA, we found two with a suggestive association with VT recurrence: hsa-miR-27b-3p \[HR = 0.4 (0.2--0.79), *P* = 0.016\] and hsa-miR-222-3p \[HR = 1.76 (1.01--3.08), *P* = 0.049\] ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S3](#sup1){ref-type="supplementary-material"}*).

###### 

Association of terminal miRNAs with VT outcomes in the MARTHA miRNA study

  miRNA              VT recurrence       Pulmonary embolism vs. deep vein thrombosis                       
  ------------------ ------------------- --------------------------------------------- ------------------- -------
  hsa-miR-370-3p     1.77 (1.09--2.88)   0.019                                         0.72 (0.49--1.05)   0.090
  hsa-miR-184        0.53 (0.30--0.95)   0.024                                         1.23 (0.92--1.66)   0.153
  hsa-miR-4732-5p    0.41 (0.18--0.92)   0.024                                         0.70 (0.39--1.22)   0.218
  hsa-miR-4433b-3p   1.54 (1.04--2.29)   0.033                                         1.01 (0.75--1.36)   0.930
  hsa-miR-215-5p     0.63 (0.37--1.09)   0.091                                         1.11 (0.73--1.67)   0.633
  hsa-miR-134-5p     1.58 (0.85--2.91)   0.142                                         0.89 (0.57--1.39)   0.601
  hsa-miR-381-3p     1.45 (0.83--2.56)   0.194                                         0.81 (0.53--1.23)   0.327
  hsa-miR-145-3p     0.51 (0.15--1.76)   0.278                                         0.62 (0.24--1.56)   0.311
  hsa-miR-23a-3p     0.67 (0.26--1.70)   0.393                                         1.00 (0.51--1.93)   0.999
  hsa-miR-197-3p     0.78 (0.35--1.76)   0.555                                         1.41 (0.79--2.56)   0.251
  hsa-miR-150-3p     1.23 (0.53--2.83)   0.629                                         0.90 (0.49--1.66)   0.743
  hsa-miR-484        1.20 (0.56--2.59)   0.637                                         1.27 (0.69--2.38)   0.447
  hsa-miR-199a-3p    0.80 (0.22--2.86)   0.726                                         1.17 (0.46--2.97)   0.746
  hsa-miR-378d       0.81 (0.15--4.56)   0.812                                         0.41 (0.10--1.46)   0.184
  hsa-miR-20a-5p     1.09 (0.40--2.95)   0.863                                         0.74 (0.36--1.52)   0.411

*P*-values were obtained from the Likelihood Ratio test statistic associated with a Cox survival model adjusted for age, sex, BMI, and smoking.

*P*-values obtained from a logistic model adjusted for age, sex, BMI, and smoking.

miR-eQTL analyses
-----------------

At the pre-specified genome-wide statistical level of 3.2 × 10^−10^, three SNP × miRNA associations, all *cis*, were identified in the MARTHA study (*Table [3](#suaa008-T3){ref-type="table"}*). These were observed for rs12473206 with hsa-miR-4433b-3p (*P* = 8.12 × 10^−35^), rs2127870 with hsa-miR-625-3p (*P* = 9.57 × 10^−26^), and rs140930133 with hsa-miR-941 (*P* = 5.07 × 10^−15^). The latter two have already been observed in whole blood[@suaa008-B36] and adipose tissue.[@suaa008-B37] Using a more liberal miRNA-wide threshold of *P* = 5 × 10^−8^, 10 additional suggestive associations, 1 in *cis* and 9 in *trans*, were observed (*Table [3](#suaa008-T3){ref-type="table"}*). Regional association plots and boxplot summarizing the genotype × miRNA associations at these 13 main candidates are shown in [Supplementary material online](#sup1){ref-type="supplementary-material"}.

###### 

Significant associations at the 5⋅10^−8^ statistical level between SNPs and plasma miRNA levels in the MARTHA miRNA study

  miRNA                  miRNA host gene   Top SNP Associated   MAF    r^2^   Chr   Distance to 5' miRNA   Effect (SD)      *P*-value      SNP Genomic Context
  ---------------------- ----------------- -------------------- ------ ------ ----- ---------------------- ---------------- -------------- ------------------------------
  *Cis* associations                                                                                                                       
   hsa-miR-4433b-3p      Intergenic        rs12473206           0.23   0.99   2     −13                    0.979 (0.080)    8.12⋅10^−35^   exonic_ncRNA (hsa-miR-4433b)
   hsa-miR-625-3p        FUT8              rs2127870            0.27   0.99   14    141 025                0.533 (0.051)    9.57⋅10^−26^   Intergenic
   hsa-miR-941           DNAJC5            rs140930133          0.19   0.97   20    8822                   −0.349 (0.045)   5.07⋅10^−15^   Intronic (DNAJC5)
   hsa-miR-432-5p        RTL1              rs201969986          0.29   0.95   14    177 423                −0.346 (0.063)   3.31⋅10^−8^    Intergenic
  *Trans* associations                                                                                                                     
   hsa-miR-184                             rs144867605          0.07   0.82   11    75 957 983             0.804 (0.134)    2.02⋅10^−9^    Intergenic
   hsa-miR-654-5p                          rs11109171           0.44   0.99   12    98 098 091             −0.246 (0.042)   3.28⋅10^−9^    Intergenic
   hsa-miR-320c                            rs10151482           0.06   0.93   14    41 934 917             0.427 (0.074)    6.47⋅10^−9^    Intergenic
   hsa-miR-184                             rs143007764          0.06   0.65   3     142 899 139            0.916 (0.161)    1.14⋅10^−8^    Intergenic
   hsa-miR-1-3p                            rs73245753           0.12   0.79   4     26 292 392             0.589 (0.105)    2.31 10^−8^    Intergenic
   hsa-miR-330-3p                          rs1554362            0.45   0.82   2     101 221 457            −0.227 (0.041)   2.81⋅10^−8^    Intronic (LINC01849)
   hsa-miR-582-3p                          rs4522365            0.13   0.83   15    29 964 742             0.314 (0.057)    2.91⋅10^−8^    Intergenic
   hsa-miR-4446-3p                         chr12:95274192:I     0.09   0.61   12    95 274 192             −0.492 (0.089)   3.07⋅10^−8^    Intergenic
   hsa-miR-320d                            rs12800249           0.05   0.63   11    21 240 436             0.481 (0.088)    4.33⋅10^−8^    Intronic (NELL1)

MAF, minor allele frequency; *r*^2^, imputation quality criterion.

Of note, the most significant association was observed between hsa-miR-4433b-3p and rs12473206, a variant located within the mature miRNA sequence. It can be speculated that this variant impacts the maturation process of the miRNA or its target spectrum, and thus influences its plasma expression levels. In addition, two SNPs with *cis* effects on miRNA levels (thereafter referred to as *cis* miSNPs) have been previously found to associate with levels of the protein encoded by the miRNA host gene. In whole blood, the miSNP rs2127870 was reported to influence FUT8 levels,[@suaa008-B38]*FUT8* being the host gene for hsa-miR-625-3p. Similarly, the *DNAJC5* rs2427555 that is in very strong linkage disequilibrium (LD) with the miSNP rs140930133, we here found associated with plasma hsa-miR-941 levels, has been reported to influence the expression of *DNAJC5* in lymphoblastoid cells.[@suaa008-B39] These observations are supportive elements for the observed miSNP associations and would suggest a joint regulation of hsa-miR-625-3p and hsa-miR-941 expressions with those of their host genes as already documented for several miRNAs.[@suaa008-B40]

One *trans*-eQTL located in the long non-coding RNA (lncRNA) LINC01849 was associated with hsa-miR-330-3p. The identified *trans* miSNP, rs1554362, is also an eQTL for the PDCL3 transcript levels in different tissues according to the GTeX database.[@suaa008-B41] Another intronic miSNP located in the *NELL1* gene was associated with hsa-miR-320d levels. The seven other *trans* eQTL are located in intergenic regions.

We sought to *in silico* replicate these miSNP associations using the results from Nikpay *et al*.[@suaa008-B31] who scanned for genetic polymorphisms associated with miRNA levels in 710 plasma samples. Unfortunately, as the Nikpay *et al*. study relied on a genotyping array focusing mainly on coding regions and used a very stringent imputation quality criterion (*r*^2^ \> 0.9), it was not possible to assess all our candidate associations. Only four were testable (hsa-miR-941 × rs140930133, hsa-miR-432-5p × rs201969986, hsa-miR-654-5p × rs11109171, hsa-miR-320c × rs10151482) among which only the association of rs140930133 with hsa-miR-941 levels replicated (*P* = 6.3 × 10^−11^).

Conversely, we looked into the MARTHA results to replicate the 223 miSNP associations that were significantly (*P* \< 5 × 10^−8^) detected in the Nikpay *et al*. study. We were able to test 92 of them among which 37 replicated at the nominal level of *P* = 0.05 in MARTHA (*Table [4](#suaa008-T4){ref-type="table"}*). These involved 29 *cis* and 8 *trans* miSNP associations.

###### 

Association of SNPs with plasma miRNA levels identified in Nikpay *et al*.[@suaa008-B31] that nominally replicated (*P* \< 0.05) in MARTHA miRNA study

                                                           NIKPAY (*N* = 710)   MARTHA (*n* = 344)                                                            
  ---------------------- ------------ ---- ----------- --- -------------------- -------------------- ------- ----------------- ------ ------ -------- ------- ----------------
  *Cis* associations                                                                                                                                          
   miR-941               rs2427550    20   62547575    A   0.23                 −0.157               0.023    3.96 × 10^−11^   0.19   0.99   −0.339   0.044    5.76 × 10^−15^
   miR-584-5p            rs17795259   5    148416952   C   0.15                 0.268                0.018    1.35 × 10^−45^   0.15   0.99   0.213    0.043    4.82 × 10^−7^
   miR-4433b-5p          rs2059631    2    64574682    A   0.43                 0.289                0.017    1.57 × 10^−56^   0.45   1.00   0.129    0.029    4.96 × 10^−6^
   miR-139-3p            rs4944563    11   72316881    C   0.17                 0.169                0.026    1.18 × 10^−10^   0.14   1.00   0.182    0.042    6.82 × 10^−6^
   miR-181a-5p           rs74746864   1    199023240   G   0.11                 0.175                0.025    4.12 × 10^−12^   0.13   0.95   0.221    0.066    4.27 × 10^−4^
   miR-425-5p            rs7623513    3    142100428   C   0.15                 −0.044               0.007    7.48 × 10^−10^   0.12   0.95   −0.166   0.054    1.04 × 10^−3^
   let-7e-5p             rs2198171    19   52174483    G   0.27                 −0.089               0.014    3.10 × 10^−10^   0.25   0.97   −0.124   0.043    1.83 × 10^−3^
   miR-197-3p            rs7355073    1    110129740   T   0.16                 −0.078               0.011    1.23 × 10^−12^   0.19   1.00   −0.118   0.041    2.10 × 10^−3^
   miR-26b-5p            rs12623740   2    219665715   A   0.49                 −0.060               0.007    3.37 × 10^−18^   0.51   0.99   −0.138   0.051    3.24 × 10^−3^
   miR-152-3p            rs9910516    17   46183160    A   0.23                 0.093                0.016    1.52 × 10^−08^   0.27   0.95   0.089    0.033    3.44 × 10^−3^
   miR-27b-3p            rs10993381   9    97639463    T   0.07                 0.170                0.016    2.00 × 10^−24^   0.06   0.99   0.148    0.055    3.86 × 10^−3^
   miR-182-5p            rs2693738    7    129431977   G   0.32                 0.115                0.020    2.36 × 10^−08^   0.37   0.82   0.166    0.063    4.30 × 10^−3^
   miR-181a-3p           rs1434282    1    199010721   C   0.27                 0.211                0.022    9.03 × 10^−21^   0.26   0.98   0.122    0.048    5.57 × 10^−3^
   miR-181a-5p           rs12125200   1    198992043   A   0.27                 0.340                0.013    1.13 × 10^−111^  0.24   0.96   0.124    0.049    5.79 × 10^−3^
   miR-584-5p            rs4147470    5    148528107   T   0.49                 −0.131               0.014    7.71 × 10^−20^   0.51   1.00   −0.081   0.032    6.15 × 10^−3^
   miR-26b-5p            rs833083     2    219336959   T   0.41                 −0.076               0.006    3.96 × 10^−30^   0.43   0.81   −0.137   0.057    7.96 × 10^−3^
   miR-181a-5p           rs878254     1    199257141   A   0.48                 −0.122               0.015    3.54 × 10^−15^   0.49   0.90   −0.104   0.045        0.010
   miR-181a-5p           rs2360961    1    199000277   C   0.40                 −0.151               0.016    4.39 × 10^−20^   0.40   0.94   −0.095   0.043        0.014
   miR-30d-5p            rs13282464   8    135707922   T   0.15                 0.092                0.007    2.02 × 10^−33^   0.17   1.00   0.047    0.023        0.020
   miR-4433b-5p          rs6740438    2    64528086    C   0.13                 0.163                0.029    1.78 × 10^−08^   0.15   0.98   0.083    0.041        0.022
   miR-30d-5p            rs13268530   8    135727196   T   0.15                 0.095                0.007    1.68 × 10^−35^   0.17   0.99   0.045    0.023        0.024
   miR-21-5p             rs2665392    17   57809453    A   0.16                 0.059                0.011    3.59 × 10^−08^   0.16   0.88   0.078    0.041        0.027
   miR-4433b-5p          rs35503140   2    64539015    C   0.21                 −0.130               0.022    9.86 × 10^−09^   0.19   0.95   −0.071   0.037        0.029
   miR-584-5p            rs9325124    5    148248818   A   0.39                 −0.085               0.015    7.62 × 10^−09^   0.45   1.00   −0.056   0.031        0.036
   miR-181a-5p           rs3861924    1    199121330   A   0.18                 0.137                0.020    2.06 × 10^−11^   0.20   0.96   0.097    0.054        0.037
   miR-1908-5p           rs174561     11   61582708    C   0.30                 0.151                0.012    4.76 × 10^−31^   0.26   1.00   0.052    0.030        0.040
   miR-151a-3p           rs11167012   8    141968408   A   0.42                 0.059                0.006    3.79 × 10^−24^   0.40   1.00   0.061    0.036        0.045
   miR-139-3p            rs10898849   11   72269302    T   0.25                 0.124                0.022    3.30 × 10^−08^   0.27   1.00   0.054    0.032        0.046
   let-7i-5p             rs6581454    12   62934442    G   0.47                 0.039                0.006    3.04 × 10^−11^   0.44   0.99   0.034    0.021        0.049
  *Trans* associations                                                                                                                                        
   miR-222-3p            rs11070216   15   39817245    T   0.19                 −0.067               0.012    4.87 × 10^−08^   0.19   0.97   −0.198   0.051    5.06 × 10^−5^
   miR-222-3p            rs970280     15   39864403    G   0.32                 −0.064               0.010    8.79 × 10^−10^   0.32   0.94   −0.113   0.042    3.57 × 10^−3^
   miR-143-3p            rs4734879    8    106583124   G   0.28                 0.239                0.031    2.88 × 10^−14^   0.24   0.96   0.098    0.038    5.60 × 10^−3^
   miR-1-3p              rs11906462   20   61158952    T   0.20                 0.310                0.033    6.28 × 10^−20^   0.23   0.42   0.262    0.116        0.012
   miR-320a              rs1443651    2    68569316    G   0.45                 −0.036               0.006    7.12 × 10^−10^   0.44   1.00   −0.053   0.028        0.029
   miR-16-5p             rs137214     22   35288857    T   0.28                 0.041                0.007    1.76 × 10^−08^   0.29   0.97   0.088    0.050        0.040
   miR-126-3p            rs600038     9    136151806   C   0.21                 0.055                0.009    5.95 × 10^−09^   0.34   1.00   0.041    0.024        0.041
   miR-320c              rs1443651    2    68569316    G   0.45                 −0.031               0.005    2.77 × 10^−10^   0.44   1.00   −0.066   0.039        0.045

One-sided test *P*-value.

EA, effect allele; EAF, effect allele frequency.

Among these eight *trans* miSNP associations, three deserve to be highlighted. First, plasma levels of hsa-miR-143-3p were influenced by the intronic *ZFPM2* rs4734879, *ZFPM2* being a locus reported to associate with venous thrombosis risk[@suaa008-B42] and platelet function.[@suaa008-B43] In MARTHA, plasma levels of hsa-miR-143-3p were negatively significantly correlated with BMI (*ρ* = −0.24, *P* = 3.6 × 10^−4^) and borderline significant with PAI-1 activity levels (*ρ* = −0.21, *P* = 5.3 × 10^−3^) ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S2](#sup1){ref-type="supplementary-material"}*). Second, hsa-miR-126-3p plasma levels were associated with the rs600038 located in the promoter region of the *ABO* gene. This polymorphism is in strong LD with several other *ABO* polymorphisms that are known to associate with VT risk, including the rs579459 (*r*^2^ = 0.99) tagging for the A1 ABO blood group. In MARTHA, plasma levels of hsa-miR-126-3p were strongly and positively correlated (*ρ* ∼ 0.20) with red cells (*P* = 1.73 × 10^−5^), lymphocytes (*P* = 2.5 × 10^−4^), platelets (*P* = 5.9 × 10^−4^), and polynuclear (*P* = 6.0 × 10^−4^) ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S2](#sup1){ref-type="supplementary-material"}*). Third, polymorphisms (rs970280, rs11070216) in the promoter region of the *THBS1* gene were found associated with plasma levels of hsa-miR-222-3p. This miRNA has been previously reported to associate with the risk of VT recurrence[@suaa008-B13] and has a suggestive association (*P* = 0.049) in our study ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S3](#sup1){ref-type="supplementary-material"}*), where it positively correlated with antithrombin levels (*ρ* = 0.21, *P* = 8.8 × 10^−4^) ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S2](#sup1){ref-type="supplementary-material"}*). THBS1 encodes Thrombospondin-1 and is known to be involved in angiogenesis and platelet aggregation.[@suaa008-B44]^,^[@suaa008-B45]

Finally, we performed a random-effect meta-analysis of both datasets in order to discover additional miSNPs. At the 5 × 10^−8^ statistical threshold, we identified seven new *cis* and five new *trans* miSNP associations (*Table [5](#suaa008-T5){ref-type="table"}*). None of these miSNP associations appeared to involve loci with documented link with thrombosis related traits.

###### 

Significant (*P* \< 5 × 10^−8^) associations of miSNP with miRNA plasma levels derived from the MARTHA miRNA and Nikpay *et al*.[@suaa008-B31] meta-analysis

                                                           MARTHA   Nikpay   Combined                                                                                        
  ---------------------- ---- ----------- ------------ --- -------- -------- ---------- ------- ------------- ------- -------- ------- ------------- ------ -------- ------- -------------
  *Cis* associations                                                                                                                                                         
   miR-181b-5p           1    199257141   rs878254     A   0.485    0.90     −0.054     0.032   0.0916        0.480   −0.071   0.013   1.64 10^−7^   0.61   −0.069   0.012   3.18 10^−8^
   miR-148a-3p           7    25991977    rs9639523    T   0.375    0.87     −0.081     0.034   0.0191        0.344   −0.072   0.013   2.03 10^−7^   0.80   −0.073   0.013   8.41 10^−9^
   let-7a-5p             9    96916230    rs10512230   T   0.287    1.00     0.040      0.031   0.1934        0.315   0.026    0.004   6.49 10^−8^   0.67   0.027    0.005   2.19 10^−8^
   let-7d-5p             9    97229465    rs4497033    T   0.492    0.99     −0.061     0.036   0.0895        0.463   −0.028   0.005   1.50 10^−7^   0.36   −0.029   0.005   3.85 10^−8^
   miR-2110              10   115933905   rs17091403   T   0.091    1.00     −0.141     0.043   1.13 10^−3^   0.074   −0.103   0.023   9.90 10^−6^   0.44   −0.112   0.020   4.34 10^−8^
   miR-342-3p            14   100256449   rs8011282    C   0.474    0.99     0.095      0.030   1.39 10^−3^   0.487   0.067    0.014   5.65 10^−6^   0.41   0.073    0.013   3.68 10^−8^
   miR-99b-5p            19   52160843    rs11084100   C   0.392    1.00     −0.067     0.024   5.17 10^−3^   0.419   −0.065   0.012   1.12 10^−7^   0.94   −0.066   0.011   1.50 10^−9^
  *Trans* associations                                                                                                                                                       
   miR-215-5p            2    171402733   rs724806     C   0.252    0.97     0.091      0.057   0.1123        0.326   0.143    0.027   1.44 10^−7^   0.40   0.134    0.024   4.09 10^−8^
   miR-10b-5p            7    13236107    rs6948643    G   0.264    1.00     −0.071     0.040   0.0766        0.285   −0.09    0.017   2.84 10^−7^   0.66   −0.087   0.016   4.62 10^−8^
   let-7d-3p             11   2611449     rs1024164    A   0.133    0.87     −0.083     0.034   0.0147        0.092   −0.065   0.013   7.78 10^−7^   0.63   −0.068   0.012   3.18 10^−8^
   miR-378a-3p           11   133763476   rs10894759   A   0.317    0.99     0.066      0.028   0.0206        0.296   0.059    0.011   7.86 10^−7^   0.82   0.060    0.011   3.58 10^−8^
   miR-7-5p              15   41614621    rs7163989    G   0.293    0.99     −0.112     0.041   6.68 10^−3^   0.278   −0.089   0.016   1.48 10^−7^   0.61   −0.093   0.016   2.70 10^−9^

EAF, estimated allele frequency; *r*^2^, imputation quality criterion; β, allele effect.

*P*-value of the test for heterogeneity between the MARTHA and Nikpay studies.

*P*-value of the combined effect obtained through a random-effect meta-analysis of the results of both studies.

Discussion and conclusion
=========================

In this study, we reported the largest investigation to date of miRNA plasma profiling in a cohort of VT patients. Capitalizing on the application of a next-generation sequencing technology, known to be more efficient and sensitive to detect and quantify miRNAs compared with microarray or RT-qPCR techniques, we were able to detect 162 highly expressed miRNAs. These miRNAs were then tested for association with several VT-related phenotypes including 38 haematological traits and VT recurrence. In order to deal with the correlation between miRNA levels and reduce the multiple testing burden associated with the number of tested miRNAs, we deployed an original BN analysis aimed at identifying miRNAs that could serve as more powerful biomarkers for the investigated traits. In addition, as our studied VT patients had been previously typed for genome-wide genotypes, we were able to perform GWAS on each of the 162 miRNAs, and combined our results with some previously obtained in disease-free individuals in order to identify novel associations of common SNPs with plasma miRNA levels.

Several conclusions could be derived from this work. First, we did not identify any miRNA that significantly associated with the risk of VT recurrence. In our study, the miRNA that discriminated the most between patients with or without recurrence, but also between DVT vs. PE patients, was the hsa-miR-370-3p. Several works have already reported the involvement of has-miR-370-3p in lipids metabolism[@suaa008-B46] and one of the most robust target gene for hsa-miR-370-3p is *CPT1A*[@suaa008-B50] whose role in lipid metabolism is also very documented.[@suaa008-B51] Hsa-miR-370-3p is also predicted to target drug-metabolism genes, such as *CYP2D6* and *VKORC1L1*,[@suaa008-B50] that are related to the warfarin anticoagulant pharmacotherapy. Aside this miRNA, we observed a trend of association with VT recurrence for the hsa-mir-27b-3p and hsa-miR-222-3p that had been previously identified in Wang *et al*.[@suaa008-B13] but these associations (*P* = 0.016 and *P* = 0.0495, respectively) did not survive any multiple testing correction ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S3](#sup1){ref-type="supplementary-material"}*). Larger studies would be mandatory to confirm these observations and increase our chance to identify other miRNAs associated with the risk of recurrence in VT patients. Second, we observed several significant associations of miRNAs with haematological traits that deserve further replication in independent studies. One can highlight the significant correlation between haematocrit levels and plasma levels of hsa-miR-199b-3p, a miRNA that has been reported to be associated with VT risk.[@suaa008-B12] Third, our miR-QTL study identified about 25 significant (*P* \< 5 × 10^−8^) associations of SNPs with plasma miRNA levels, of which, to the best of our knowledge, 21 have never been reported, including a dozen of *trans* associations. These associations could help deciphering the genomic architecture of complex diseases where miRNAs are involved. For example, plasma levels of hsa-miR-143-3p were found to be associated with the rs4734879 mapping to *ZFPM2,* a gene known to associate with platelet function[@suaa008-B43] and VT risk.[@suaa008-B42] We also observed a strong association of rs12473206 with plasma levels of hsa-miR-4433b-3p, a miRNA whose serum levels have recently shown to be associated with stroke.[@suaa008-B54] The impact of this SNP on stroke risk deserves to be further and deeply investigated. The results of our GWAS on miRNA levels were combined with those obtained by Nikpay *et al*.[@suaa008-B31] and freely available at <https://zenodo.org/>. However, only SNPs with imputation quality greater than 0.90 are available at this resource, which has hampered our ability to replicate some of the main associations observed in the MARTHA miRNA study. To facilitate future studies aimed at disentangling the genetic regulation of miRNAs, the results of the 162 GWAS performed on miRNA levels in MARTHA will be available for download at <https://zenodo.org/>.

Altogether, this study produced a rich source of information relating to plasma miRNAs and biological/clinical traits associated with VT that could be of great use to generate and/or validate new hypothesis.
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